CCCC

C4 Therapeutics
$3.59
+$0.19 (+5.59%)Jul 27, 2026
3.2FairMoatMint rating

MoatMint rates C4 Therapeutics (CCCC) 3.2 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 2.3 out of 10.

Key metrics

The numbers that frame CCCC today
Market cap
$396.94M
P/E (TTM)
-3.8
EV / FCF
-4.1
Gross margin
100%
EV / Sales
11.2
ROIC
-38.9%
Div yield
0%
Debt / equity
0.3
52wk Low
$1.69
52wk High
$5.17

CCCC stock rating

How CCCC scores on quality, value, growth, momentum and financial health
3.2out of 10
Fair overallFair business, expensive priceTop 68% of ~5,000 US stocks
QualityFair2.3/10
GrowthFair2.7/10
MomentumGreat9.5/10
ValuePoor1.4/10
Financial HealthFair3.2/10

Growth

Revenue and earnings trend for CCCC
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about CCCC
Is C4 Therapeutics a good buy?
Hold. C4 Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think C4 Therapeutics is selling at a very high price.
What is the market capitalization of CCCC?
C4 Therapeutics's market capitalization is $396.94M.
What is the P/E ratio for CCCC stock?
C4 Therapeutics's current P/E ratio is -3.8.
What is the 52-week high for CCCC stock?
The 52-week high for C4 Therapeutics is $5.17. The current close of $3.59 is 30.6% below that high.
What is the 52-week low for CCCC stock?
The 52-week low for C4 Therapeutics is $1.69. The current close of $3.59 is 112.4% above that low.
Does CCCC stock pay dividends?
C4 Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for CCCC?
C4 Therapeutics's Debt / Equity ratio is 0.25.